ID 112041
Title Alternative
The development and the perspective of Artificial Pancreas
Author
Keywords
Continuous Glucose Monitoring(CGM)
Artificial pancreas
Insulin pump
Type1diabetes
Content Type
Journal Article
Description
Diabetes is characterized as a chronic hyperglycemic status caused by insulin insufficiency from pancreatic beta cells. The artificial pancreas is consisted of Continuous Glucose Monitoring (CGM) and insulin delivery according to the sensor glucose monitoring values. CGM does not monitor blood glucose concentration, but monitors subcutaneous glucose concentration, which is dispersed from blood vessel. The delay of glucose values of CGM is approximately 5 to 10 minutes compared with blood glucose values. Sensor augmented insulin pump 620G, which combines insulin pump and real time CGM is available from February 2015 in Japan. There are two more functions available from spring of 2017 in the United States, in addition to the 620G pump ; i.e. predictive low glucose suspend function, which suspend insulin delivery when hypoglycemia is predicted, and automated basal insulin increase when sensor glucose is high. The development of insulin infusion algorithm is still on the way, however, automated meal time insulin delivery will be introduced near future.
Journal Title
Shikoku Acta Medica
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
73
Issue
5-6
Start Page
221
End Page
226
Sort Key
221
Published Date
2017-12-25
FullText File
language
jpn
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences